BioSpace News Archive

While COVID-19 vaccines are being administered in hopes of reducing the impact of the pandemic, novel variants of SARS-CoV-2, the virus that causes COVID-19, are spreading at accelerated rates.

Brii Biosciences, a multi-national company developing innovative therapies for diseases with significant unmet medical needs and with a high public health impact, announced that its antibodies BRII-196 and BRII-198 failed to meet pre-specified efficacy criteria permitting expansion into the Phase 3 component of ACTIV-3.

The researchers can comment on a wide range of topics from a science-based perspective and are available for media interviews

VYNE Therapeutics Inc. announced that David Domzalski, Chief Executive Officer, will present and participate at the Barclays Global Healthcare Conference and H.C. Wainwright Global Life Sciences Conference.

Companies will combine their unique scientific and technical expertise to develop a first-in-class anti-SIRPα antibody conjugated to TLR9 agonist (“SIRPα TRAAC”) that delivers targeted immune activation

Interim review by independent data monitoring committee (DMC) found no meaningful reduction in the overall mortality rate in Phase 1/2 study

Chiasma, Inc., a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce the burden of chronic injections for people with rare diseases, as evidenced by its recent initiation of a phased U.S. commercial launch of MYCAPSSA® as the first oral therapy for treatment of acromegaly, announced financial results for the fourth quarter and year ended December 31, 2020 and provided a business update.

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, announced that it will report fourth quarter and full year 2020 financial and operating results on Tuesday, March 16, 2021.

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced it will release its financial results for the fourth quarter and full year of 2020 on Thursday, March 18, 2021.